British builders grow more pessimistic: PMI rises to an eight-month high, but major projects are still being collectively shelved
UK builders became more pessimistic in September. The PMI rose to an eight-month high of 46.1 but remains in contraction territory; weak orders and Middle East conflicts are causing companies to delay project decisions.
Zhihu Finance APP has noted that a key survey shows British builders became less optimistic about the outlook in September, with many postponing major project decisions, even though there are signs the industry's downturn is easing.
The S&P Global Purchasing Managers' Index (PMI) rose to an eight-month high of 46.1, up from 44.3 in August. This result is better than economists' expectations of 44.9, but the sector still remains below the 50 threshold that separates output growth from contraction.
Although the residential construction sub-index improved, it remains deeply in contraction territory, continuing a prolonged slump that has dashed the Labour Government's hopes of leading a housing boom.
The downturn in the UK construction industry continued in September
Rising interest rates, inflation, and weak orders have dampened the sector's growth prospects, with companies postponing decisions due to uncertainty caused by Middle East conflicts. The future activity index fell to its lowest since May.
Tim Moore, Director of Economics at S&P Global Market Intelligence, said, "Total new orders were relatively weak in September, and construction firms reported longer sales conversion cycles with clients delaying major project decisions." "This was attributed to weak demand and geopolitical tensions, with some businesses also noting severe input cost increases putting them under pressure."
When the war between the US and Iran broke out and inflationary pressures surged once again, the construction industry was already in a prolonged slump. It has consistently been the weakest link among the UK’s private sectors covered by the PMI survey, while the services and manufacturing sectors have so far weathered the shock of the conflict.
Just before the outbreak of war, builders saw their costs rise at the slowest pace in seven months. However, Moore warned that the trend of easing price pressures "seems unlikely to persist given the recent rise in fuel prices and transportation costs."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Updated version 2 - McKesson and CD&R will privatize infusion therapy service provider Option Care in a $5.8 billion deal.
Reuters, October 6 – Pharmaceutical distributor McKesson (MCK.N) and private equity firm Clayton Dubilier & Rice (CD&R) reached an agreement on Tuesday to take infusion therapy provider Option Care Health (OPCH.O) private, in a deal valued at approximately $5.8 billions, including debt. The acquisition offer of $32.05 per share represents a 37.1% premium over Option Care's most recent closing price. As a US pharmaceutical distributor, McKesson is seeking to expand its healthcare services portfolio, and this transaction marks its latest move. It also follows the private equity fund’s previous acquisition of another home health service provider, Enhabit. Option Care Health is the largest independent provider of infusion therapy services in the US, serving over 308,000 patients annually through more than 197 service centers, offering home and outpatient infusions, specialty pharmacy, and care for complex conditions. With an aging population and a growing number of patients choosing care outside costly hospital settings, demand for home healthcare in the US continues to increase. Upon closing, CD&R will hold the majority stake, while McKesson will retain a minority interest. Option Care Health will continue to operate as an independent company led by its existing management team. As per transaction terms, McKesson will invest about $1.4 billions to acquire a 49% stake, with the right to acquire CD&R's remaining 51% interest at a later date. According to Michael Cherny, an analyst at Leerink Partners, this deal positions McKesson in line with the trend of healthcare services shifting away from hospitals and medical institutions to alternative sites of care. Additionally, given McKesson’s current operation of Canada’s leading infusion and injection network, Inviva, the transaction extends its reach in the US home infusion market. McKesson’s oncology and multi-specialty business segments, including infusion services, posted revenues of $14.2 billions in the most recent quarter, up 33% year-over-year, benefiting from specialty drug distribution and contributions from acquisitions. The deal is expected to close in the first half of 2027, after which Option Care Health will become a private company.
The Bank of England's most hawkish official: The labor market is "stationary" rather than loose, and inflation is deeply entrenched.
The Bank of England hawkish official Mann stated that the labor market is "static" rather than loose, and warned that inflation is deeply entrenched; rising fuel and energy prices may cause inflation to "significantly exceed 4%" early next year.
BUZZ - Bank of America gives Diodes a "Buy" rating, driving its stock price up
October 6 - Semiconductor product manufacturer Diodes (DIOD.O) saw its stock price rise 3.38% in pre-market trading to $107.64. BofA has initiated coverage of DIOD with a “Buy” rating and a price target of $135, implying about 30% upside from the previous closing price. According to the report, DIOD holds a favorable position in the automotive, industrial, and AI data center semiconductor markets, positioning it to expand its market share. The increasing use of semiconductors in automobiles and growing demand for AI infrastructure are expected to drive the company’s long-term growth. The firm anticipates that DIOD’s AI data center business—which currently accounts for about 12% of total revenue—could triple by 2030. As of the previous trading day’s close, the stock’s year-to-date growth has already more than doubled. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Automated translations may contain errors or lack context and are provided solely for the convenience of readers. Reuters accepts no liability for any damages or losses resulting from the use of automated translation features.)
BUZZ-BridgeBio shares rise as FDA initiates priority review for dwarfism drug
On October 6th, shares of pharmaceutical company BridgeBio Pharma (BBIO.O) rose 2.5% in pre-market trading to $67.80. The company announced that the U.S. Food and Drug Administration (FDA) has granted priority review to its application seeking approval for the investigational oral drug infigratinib for the treatment of children with achondroplasia, the most common type of dwarfism. The FDA has set a target decision date of February 4, 2027. The application is based on a late-stage clinical trial that met both primary and key secondary endpoints; children treated with infigratinib experienced an adjusted annual growth velocity 1.74 centimeters greater than those given placebo. The drug also improved arm span and body proportions in children under eight years old. No serious adverse events or discontinuations related to the drug were reported. BridgeBio plans to apply for European approval in the fourth quarter of 2026. As of the close of the previous trading day, BBIO shares are down 13.5% year-to-date. (For the convenience of non-English speakers, Reuters has automated this report into several other languages. Because automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of automated translation, which is provided for readers’ convenience only. Reuters accepts no liability for any damages or losses arising from the use of automated translation.)
Crypto prices
More
